Cytarabine
| Evidence Level: L5 | Predicted Indications: 55 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Cytarabine |
| DrugBank ID | DB00987 |
| Brand Names (EU) | Cytarabine, Vyxeos liposomal (previously Vyxeos) |
| Evidence Level | L5 |
| Predicted Indications | 55 |
| Top Prediction Score | 99.78% |
Approved Indication (EMA)
Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | small cell lung carcinoma | 99.78% | DL |
| 2 | primary pulmonary lymphoma | 99.78% | DL |
| 3 | well-differentiated fetal adenocarcinoma of the lung | 99.76% | DL |
| 4 | pulmonary blastoma | 99.76% | DL |
| 5 | myeloid leukemia | 99.61% | DL |
| 6 | upper aerodigestive tract neoplasm | 99.49% | DL |
| 7 | ganglioneuroblastoma (disease) | 99.36% | DL |
| 8 | vertebral anomalies and variable endocrine and T-cell dysfunction | 99.32% | DL |
| 9 | retroperitoneal neoplasm | 99.23% | DL |
| 10 | neuroblastoma | 99.19% | DL |
| 11 | acute lymphoblastic/lymphocytic leukemia | 99.16% | DL |
| 12 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | 98.96% | DL |
| 13 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | 98.96% | DL |
| 14 | acute myeloid leukemia with t(8;21)(q22;q22) translocation | 98.91% | DL |
| 15 | chronic myelogenous leukemia, BCR-ABL1 positive | 98.88% | DL |
| 16 | adenosarcoma | 98.81% | DL |
| 17 | Ewing sarcoma | 98.80% | DL |
| 18 | acute myeloid leukemia with CEBPA somatic mutations | 98.69% | DL |
| 19 | acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) | 98.69% | DL |
| 20 | uterine ligament adenosarcoma | 98.62% | DL |
Showing top 20 of 55 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.